Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Banner Year for Drug Approvals: Time to Change the Focus

This article was originally published in RPM Report

Executive Summary

FDA is entering a big legislative year with a good story to tell based on 30 new molecular entity approvals. But the level of submissions remains constant—suggesting it may be time to shift the focus from what comes out of FDA to what makes it in.


Related Content

FDA’s Very Big Year: Drug Approvals Approach Record Levels
What's "New" at FDA?
What’s Going On With Eliquis and Xarelto at FDA?
An Emerging Approval Trend At FDA: More First-Time Sponsors
Companion Drug/Diagnostic Pathway: A Question of Where and Who
The Future of Drug Regulation: An Interview With Center for Drug Evaluation & Research Director Janet Woodcock
FDA and the R&D Crisis: Time to Stop the Blame Game
Another Disappointing Year for Drug Approvals
The Impact of FDAAA On Drug Approvals: Setting the Baseline
Pyramid Schemes and Pipeline Dreams: Adapting to a Tiered Regulatory System for New Drugs


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts